Date posted: December 15, 2015, 6:00 am
In this episode, we discuss two agents newly approved for schizophrenia -- Rexulti (brexpiprazole) and cariprazine (Vraylar).
Date posted: November 24, 2015, 6:00 am
In this episode, we discuss two new anti-diabetic medications: empagliflozin (Jardiance) and the EMPA-REG OUTCOME trial as well as dulaglutide (Trulicity), a new GLP1 agonist.
Date posted: November 3, 2015, 6:00 am
In this podcast, we discuss three new injectable insulin formations: Toujeo (insulin glargine U-300), Humalog U-200 (insulin lispro), and Tresiba (insulin degludec).
Date posted: October 13, 2015, 6:00 am
In this episode, we discuss PCSK9 inhibitors, a new drug class for LDL lowering, with a particular focus on alirocumab (Praluent).
Date posted: September 22, 2015, 6:00 am
In this episode, we discuss the new drug class, ARNI, recently approved for heart failure with a focus on sacubatril/valsartan (Entresto) and the PARADIGM-HF trial.
Date posted: September 1, 2015, 6:00 am
In this episode, we discuss the therapeutic drug monitoring and dose adjustments for tacrolimus (Prograf) and lithium.
Date posted: August 11, 2015, 6:00 am
In this episode, we discuss the therapeutic drug monitoring and dose adjustments for valproic acid (Depakote/Depakene/Depakon) and digoxin (Lanoxin).
Date posted: July 21, 2015, 6:00 am
In this episode, we discuss the therapeutic drug monitoring and dose adjustments for warfarin (Coumadin) and phenytoin (Dilantin).
Date posted: June 30, 2015, 6:00 am
In this episode, we discuss malaria prophylaxis with atovaquone/proguanil, chloroquine, hydroxychloroquine, doxycycline, mefloquine, and primaquine.
Date posted: June 9, 2015, 6:00 am
In this episode, we discuss six pivotal drug classes that have been FDA approved within the past 20 years. This is part 2 of a 2 part episode.